Análisis de la acción Talphera Inc (TLPH)

Análisis de IA of Talphera Inc (TLPH)

Vender

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.

Métricas de valoración

El PER previsto actual de Talphera Inc (TLPH) es 1.02, frente a su media de 5 años de -0.85.

PER previsto

Sobrevalorado

Media 5A P/E

-0.85

P/E actual

1.02

Sobrevalorada

0.50

Infravalorada

-2.19

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-0.32

EV/EBITDA actual

-0.01

Sobrevalorada

0.83

Infravalorada

-1.48

Precio/ventas previsto

Valor razonable

Media 5A P/S

507.28

P/S actual

121.93

Sobrevalorada

2323.26

Infravalorada

-1308.69

Escenarios de precio de Alphio AI para TLPH

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%TLPH

$0.50

Precio del escenario

B

Base

Base · 50%TLPH

$0.49

Precio del escenario

B

Bajista

Bajista · 25%TLPH

$0.40

Precio del escenario

Preguntas frecuentes sobre TLPH, respondidas por Alphio AI

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.